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Psoriasis is a chronic inﬂammatory skin condition with an increased risk of cardiovascular disease. This risk has been attributed to
an association with many independent risk factors including obesity, hypertension, smoking, and dyslipidemia. Psoriasis patients
also have lower levels of folate and conversely higher levels of homocysteine, which in itself is a risk factor for cardiovascular
disease. It has been postulated that low folate levels in this group may be a direct cause of hyperhomocysteinemia and therefore
a treatable risk factor by folate supplementation. This paper looks at the literature published to date on the relationship between
psoriasis, homocysteine, and folate levels.
1.Introduction
Psoriasis is a chronic recurrent inﬂammatory skin condition.
Its prevalence varies among ethnic groups, but it aﬀects
approximately 1–3% [1] of the population in industrialised
countries. Its clinical course can vary greatly in terms of
morphology, distribution, and severity of the disease. In its
commonest subtype it is characterised by the formation of
discrete, pink, scaly plaques occurring at various sites on the
body. It aﬀe c t sm e na n dw o m e ne q u a l l ya n di ss e e ni na l l
races [2]. Although it can present at any age, it occurs most
frequently between the ages of 15 and 20 and again between
50 and 60 years of age.
Psoriasis has very signiﬁcant psychosocial morbidity
which appears independent of objective disease severity
[3, 4]. It is also associated with an increased risk of car-
diovascular disease and mortality [5–8]. Indeed patients
with psoriasis have almost twice the risk of cardiovascular
disease when compared with normal controls [9, 10].
The exact reason for this increased risk is unknown. A
number of studies have shown signiﬁcantly increased rates
of hypertension, dyslipidemia, diabetes mellitus, smoking,
and excessive alcohol consumption in patients with psoriasis
[11]. Neimann et al. found that patients with severe psoriasis
had an increased risk of diabetes (odds ratio (OR), 1.62; 95%
conﬁdence interval (CI), 1.3–2.01), obesity (OR, 1.79; 95%
CI, 1.55–2.05), and smoking (OR, 1.31; 95% CI, 1.17–1.47)
compared with controls [12]. Prodanovich et al. also found
a higher prevalence of these risk factors in patients with
psoriasis. However, even after controlling for these variables,
they found a higher prevalence of ischemic heart disease
(OR 1.78; 95% CI, 1.51–2.11), cerebrovascular disease (OR,
1.70; 95% CI, 1.33–2.17), and peripheral vascular disease
(OR,1.98;95%CI,1.32–2.82)whencomparedwithcontrols.
Indeed they also found psoriasis to be an independent risk
factor for mortality (OR, 1.86; 95% CI, 1.56–2.21) as a result
of the association with atherosclerosis [13].
These risk factors in combination with the chronic
inﬂammatory process are thought to be signiﬁcant com-
ponents in the development of vascular disease [9, 14].
Links with alterations in levels of folate and homocysteine
in patients with psoriasis have also been implicated in
contributing to the propagation of atherosclerosis and
atherothrombotic events [9, 15, 16].2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 1: Proposed mechanism of homocysteine-induced endothelial dysfunction and atherogenesis [21].
2. Pathogenesis of Low Folate
andHighHomocysteineLevelsin
Patients with Psoriasis
Recent case control studies have demonstrated that patients
with psoriasis have lower levels of folate in comparison to
normal controls [9, 15, 17, 18]. The exact aetiology of this
association remains unclear. Postulated mechanisms include
alterations in gut absorption of folate due to microscopic
inﬂammatory changes seen in the bowel mucosa of patients
with active psoriasis and psoriatic arthritis [15]. A more
likelyexplanationhoweverprobablyrelatestotheaccelerated
keratinocyte turnover seen in patients with psoriasis. This
action results in excessive consumption of folate used to
methylate DNA in these actively dividing cells thus lowering
folate levels [9].
Conversely homocysteine levels are elevated in psoriasis
patients [9, 15, 17]. In one case-controlled study this was
found to directly correlate with disease severity and to be
inversely related to plasma folate levels [15]. Plasma homo-
cysteine is an independent risk factor for cardiovascular
disease [19, 20], peripheral vascular disease, cerebrovascular
disease and possibly Alzheimer’s diseases. The magnitude of
this risk is equivalent to the risk of smoking or dyslipidemia
[9].
Hyperhomocysteinemia (>15umol/L) is thought to
favour atherosclerosis and vascular thrombosis by a number
of mechanisms. These include damaging endothelial cells,
promoting clot formation, decreasing ﬂexibility of blood
vessels leading to aortic stiﬀness, and reducing blood ﬂow
velocity[20].Theendothelialdysfunctionisthoughttoresult
from the accumulation of asymmetrical dimethylarginine
(ADMA)whichisanaturalinhibitorofnitricoxidesynthase.
As a result there is a reduction in the production of
the vasodilator nitric oxide which protects the vessel wall
against the pathogenesis of atherosclerosis and thrombosis
(Figure 1).
It has been suggested that hyperhomocysteinemia in
addition to other factors may be caused by reduced levels of
folate in these patients [9, 15]. Coenzymes methylene tetra-
hydrofolate, methylcobalamin, and pyridoxal phosphate are
essential for three of the enzymes involved in the metabolism
of homocysteine and are dependent on folate, vitamin B12
and B6, respectively. Hence in patients with severe psoriasisJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
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Figure 2: Proposed action of combination therapy, in addition to risk factors such as age, sex, hypertension, and dyslipidemia,
homocysteine and inﬂammation lead to increased incidence of vascular disease. Consequently reducing inﬂammation with methotrexate
and hyperhomocysteinemia by folic acid may lead to a decreased incidence of vascular disease for patients with psoriasis [24].
who have large areas of rapid skin turnover and increased
keratinocyteactivity,thereisexcessiveconsumptionoffolate.
This in turn results in reduced breakdown and elevated
serum levels of homocysteine with all of its adverse eﬀects.
3. Discussion
It appears from this paper that patients with psoriasis have
lower levels of folate and higher levels of homocysteine than
normal controls. As psoriasis is associated with an increased
riskofcardiovascularmorbidityandmortalityandhomocys-
teine is an independent risk factor for cardiovascular disease,
it may seem intuitive that managing this risk factor would
have beneﬁcial eﬀects in terms of cardiovascular mortality
and morbidity.
The possible beneﬁt of folate supplementation seems
logical [22]. Folate has long been used in combination
with methotrexate in the management of psoriasis, psoriatic
arthritis, and rheumatoid arthritis. Here it is eﬀective in
reducing gastrointestinal side eﬀects and liver function test
abnormalities [23]. In a retrospective cohort study looking
at over seven thousand patients with psoriasis, methotrexate
wasfoundtoreducetheincidenceofvasculardiseaseandthis
reduction was further enhanced when folic acid was added
(Figure 2)[ 24].
However, homocysteine levels can be elevated for other
reasonsincludingobesity,hypertension,smoking,andexces-
sive alcohol consumption all of which have signiﬁcant
prevalence in the psoriatic patient population [11]. Armitage
et al. in a double-blinded randomised control trial assessed
the beneﬁcial eﬀects of lowering homocysteine levels in over
12,000 post-MI patients. They failed to demonstrate any
beneﬁt in vascular outcomes from long-term reductions in
homocysteine with folate and vitamin B12 supplementation
[25]. It is possible that hyperhomocysteinemia in psoriasis
is independent of folate deﬁciency and instead is linked
with other risk factors such as hypertension and obesity [9].
“The psoriatic march”, a concept of how severe psoriasis
may drive cardiovascular morbidity, suggests a process of
genetic susceptibility triggered by environmental factors and
immune responses. This leads to disease expression and
co-morbidity resulting from chronic inﬂammation. It is this4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
chronic inﬂammatory burden and state of insulin resistance
which can result in endothelial dysfunction and ultimately
atherosclerosis [26].
4. Conclusion
It is well established that folic acid supplementation has
a role in the treatment of psoriasis in conjunction with
methotrexate treatment. However, the evidence to support
its use in reducing the risk of cardiovascular disease by
directly impacting on plasma homocysteine levels is lacking.
Certainly further work within this group is necessary. For
now management of associated risk factors such as obesity,
dyslipidemia, and hypertension as well as encouraging
smoking cessation are paramount for these patients as is, of
course, the management of their skin.
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